Search

Your search keyword '"Nagy, Orsolya"' showing total 207 results
Start Over Author "Nagy, Orsolya"
207 results on '"Nagy, Orsolya"'

3. Lymphocytic Choriomeningitis Virus Infections in Hungary between 2017–2023—Investigation of the First Congenital Infections.

Author

Koroknai, Anita, Nagy, Anna, Nagy, Orsolya, Csonka, Nikolett, Mezei, Eszter, Szomor, Katalin, and Takács, Mária

Subjects
LYMPHOCYTIC choriomeningitis virus, CONGENITAL disorders, LYMPHOCYTIC choriomeningitis, NEUROLOGICAL disorders, VIRUS diseases
Abstract

Lymphocytic choriomeningitis virus (LCMV) is a neglected rodent-borne arenavirus, primarily spread by common house mouse species. Acquired human infections range from asymptomatic to mild flu-like symptoms and self-resolving neurological diseases. In contrast, intrauterine LCMV infection is associated with high mortality and morbidity. Infection of the fetus often leads to fetal death, and surviving fetuses may develop vision impairment and central nervous system developmental disorders. LCMV is mainly diagnosed by serological methods using in-house indirect immunofluorescence assays. LCMV nucleic acid is detected by the nested RT-PCR method and confirmed by Sanger sequencing. In Hungary, 23 acquired lymphocytic choriomeningitis cases were diagnosed between 2017 and 2023. Ten out of 23 confirmed patients proved to be positive by the PCR method. Two cases of intrauterine LCMV infections were detected in 2019 and 2021, respectively. The IgG antibody titers measured in the infant's serum samples were much higher than the IgG titers of the maternal serum samples. Both IgM and IgA antibodies were detectable in the infants' sera. As the microbiological diagnosis of LCMV is rather challenging and the symptoms are very similar to the clinical picture of other common teratogenic pathogens such as cytomegalovirus or Toxoplasma gondii, intrauterine LCMV infections might still be underdiagnosed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.

Author

Pleyer, Uwe, Al-Mutairi, Salem, Murphy, Conor C., Hamam, Rola, Hammad, Shereen, Nagy, Orsolya, Szepessy, Zsuzsanna, Yan Guex-Crosier, Julian, Karina, Habot-Wilner, Zohar, and Androudi, Sofia

Abstract

Background/Aim This study evaluated real-life adalimumab impact in patients with active non-infectious intermediate, posterior, or panuveitis (NIIPPU). Methods Adults with active NIIPPU received adalimumab in this prospective, observational study (06/2017-04/2020). Patients were evaluated at baseline (V0) and four follow-up visits over 12 months (V1-V4). Primary endpoint: proportion of patients achieving quiescence (anterior chamber (AC) cells grade and vitreous haze (VH) grade=0.5+ in both eyes, no new active chorioretinal lesions) at any follow-up visit. Secondary endpoints: proportion of patients achieving quiescence at each visit; proportion of patients maintaining response; and proportion of patients with flares. Workability, visual function, healthcare resource utilisation, and safety were evaluated. Results Full analysis set included 149 patients. Quiescence at any follow-up visit was achieved by 129/141 (91%) patients. Quiescence at individual visits was achieved by 99/145 (68%), 110/142 (77%), 102/131 (78%), and 99/128 (77%) patients at V1-V4, respectively. Number of patients in corticosteroid-free quiescence increased from 51/147 (35%; V1) to 67/128 (52%; V4; p<0.05). Proportion of patients with maintained response increased from 89/141 (63%; V2) to 92/121 (76%; V4; p<0.05) and proportion of patients with flare decreased from 25/145 (17%; V1) to 13/128 (10%; V4; p=0.092). Workability and visual function improved throughout the study. Proportion of patients with medical visits for uveitis decreased from 132/149 (89%; V0) to 27/127 (21%; V4). No new safety signals were observed. Conclusion These results demonstrated adalimumab effectiveness in improving quality of life while reducing economic burden of active NIIPPU. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study

Author

Pleyer, Uwe, primary, Al-Mutairi, Salem, additional, Murphy, Conor C, additional, Hamam, Rola, additional, Hammad, Shereen, additional, Nagy, Orsolya, additional, Szepessy, Zsuzsanna, additional, Guex-Crosier, Yan, additional, Julian, Karina, additional, Habot-Wilner, Zohar, additional, and Androudi, Sofia, additional

Published
2022
Full Text
View/download PDF

26. The role of microRNAs in congenital heart disease

Author

Nagy, Orsolya, Baráth, Sándor, and Ujfalusi, Anikó

Subjects
microRNA, cardiogenesis, Review Article, congenital heart disease
Abstract

Congenital heart diseases (CHDs) are the leading inherited cause of perinatal and infant mortality. CHD refers to structural anomalies of the heart and blood vessels that arise during cardiac development and represents a broad spectrum of malformations, including septal and valve defects, lesions affecting the outflow tract and ventricules. Advanced treatment strategies have greatly improved life expectancy and led to expanded population of adult patients with CHD. Thus, a better understanding of the pathogenesis and molecular mechanisms underlying CHDs is essential to improve the diagnosis and prognosis of patients. The etiology of CHD is largely unknown, genetic and environmental factors may contribute to the disease. In addition to the mutations affecting genomic DNA, epigenetic changes are being increasingly acknowledged as key factors in the development and progression of CHDs. The posttranscriptional regulation of gene expression by microRNAs (miRs) controls the highly complex multi-cell lineage process of cardiac tissue formation. In recent years, multiplex experimental models have provided evidence that changes in expression levels of miRs are associated with human cardiovascular disease, including CHD. The newly described correlations between miRs and heart development suggest the potential importance of miRs as diagnostic markers in human cardiovascular diseases. In the future, more intensive research is likely to be carried out to clarify their contribution to personalized management and treatment of CHD patients. In this paper, we discuss the current knowledge on the causative role of miRs in cardiac development and CHDs.

Published
2019

28. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study

Author

Taylor,Peter C, Ancuta,Codrina, Nagy,Orsolya, de la Vega,María C, Gordeev,Andrey, Janková,Radka, Kalyoncu,Umut, Lagunes-Galindo,Ivan, Morović-Vergles,Jadranka, Souza,Mariana Peixoto GU e Silva de, Rojkovich,Bernadette, Sidiropoulos,Prodromos, Kawakami,Atsushi, Taylor,Peter C, Ancuta,Codrina, Nagy,Orsolya, de la Vega,María C, Gordeev,Andrey, Janková,Radka, Kalyoncu,Umut, Lagunes-Galindo,Ivan, Morović-Vergles,Jadranka, Souza,Mariana Peixoto GU e Silva de, Rojkovich,Bernadette, Sidiropoulos,Prodromos, and Kawakami,Atsushi

Abstract

Peter C Taylor,1 Codrina Ancuta,2 Orsolya Nagy,3 María C de la Vega,4 Andrey Gordeev,5 Radka Janková,6 Umut Kalyoncu,7 Ivan Lagunes-Galindo,3 Jadranka Morović-Vergles,8 Mariana Peixoto GU e Silva de Souza,9 Bernadette Rojkovich,10 Prodromos Sidiropoulos,11 Atsushi Kawakami12 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 2Department of Rheumatology, “Grigore T. Popa” University of Medicine and Pharmacy, IaÈ™i, Romania; 3AbbVie Inc, North Chicago, IL, USA; 4CEIM Investigaciones Medicas, Buenos Aires, Argentina; 5V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 6Department of Pediatric and Adult Rheumatology, Faculty Hospital Motol, Prague, Czech Republic; 7Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; 8Department of Internal Medicine, Division of Clinical Immunology, Allergology and Rheumatology, Dubrava University Hospital, University of Zagreb School of Medicine, Zagreb, Croatia; 9Santa Casa de Belo Horizonte, Belo Horizonte, Brazil; 10Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, Hungary; 11Faculty of Medicine, University of Crete, Heraklion, Greece; 12Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JapanCorrespondence: Peter C TaylorBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Headington, Oxford, OX3 7LD, UKTel +44 1865 227323Email peter.taylor@kennedy.ox.ac.ukBackground: Patients’ needs and perspectives are important determinants of treatment success in rheumatoid arthritis (RA). Assessing patients’ perspectives can help identify unmet needs and enhance the understanding of treatment

Published
2021

30. Systemic Screening for 22q11.2 Copy Number Variations in Hungarian Pediatric and Adult Patients With Congenital Heart Diseases Identified Rare Pathogenic Patterns in the Region

Author

Zodanu, Gloria Kafui Esi, primary, Oszlánczi, Mónika, additional, Havasi, Kálmán, additional, Kalapos, Anita, additional, Rácz, Gergely, additional, Katona, Márta, additional, Ujfalusi, Anikó, additional, Nagy, Orsolya, additional, Széll, Márta, additional, and Nagy, Dóra, additional

Published
2021
Full Text
View/download PDF

31. Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study

Author

Taylor, Peter C, primary, Ancuta, Codrina, additional, Nagy, Orsolya, additional, de la Vega, María C, additional, Gordeev, Andrey, additional, Janková, Radka, additional, Kalyoncu, Umut, additional, Lagunes-Galindo, Ivan, additional, Morović-Vergles, Jadranka, additional, Souza, Mariana Peixoto GU e Silva de, additional, Rojkovich, Bernadette, additional, Sidiropoulos, Prodromos, additional, and Kawakami, Atsushi, additional

Published
2021
Full Text
View/download PDF

32. Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert Laboratory Network and the Chikungunya outbreak, Thailand, 2019

Author

Venturi, Giulietta, Aberle, Stephan W, Avšič-Županc, Tatjana, Barzon, Luisa, Batejat, Christoph, Burdino, Elisa, Carletti, Fabrizio, Charrel, Rémi, Christova, Iva, Connell, Jeff, Corman, Victor Max, Emmanouil, Mary, Jääskeläinen, Anne J, Kurolt, Ivan, Lustig, Yaniv, Martinez, Miguel J, Koopmans, Marion, Nagy, Orsolya, Nguyen, Trung, Papa, Anna, Pérez-Ruiz, Mercedes, Pfeffer, Martin, Protic, Jelena, Reimerink, Johan, Rossini, Giada, Sánchez-Seco Fariñas, María Paz, Schmidt-Chanasit, Jonas, Söderholm, Sandra, Sudre, Bertrand, Van Esbroeck, Marjan, and Reusken, Chantal B

Subjects
EVD-LabNet, chikungunya, lab surveillance, Thailand, lab preparedness and response, travel
Published
2020

36. Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Author

Pavelka, Karel, primary, Szekanecz, Zoltán, additional, Damjanov, Nemanja, additional, Anić, Branimir, additional, Tomšič, Matija, additional, Mazurov, Vadim, additional, Maksimovic, Marija, additional, Nagy, Orsolya, additional, Świerkot, Jerzy, additional, Petranova, Tzvetanka, additional, Veldi, Tiina, additional, Baranauskaitė, Asta, additional, Codreanu, Catalin, additional, Andersone, Daina, additional, and Fleischmann, Roy, additional

Published
2020
Full Text
View/download PDF

39. Multi-Approach Investigation Regarding the West Nile Virus Situation in Hungary, 2018

Author

Zana, Brigitta, primary, Erdélyi, Károly, additional, Nagy, Anna, additional, Mezei, Eszter, additional, Nagy, Orsolya, additional, Takács, Mária, additional, Bakonyi, Tamás, additional, Forgách, Petra, additional, Korbacska-Kutasi, Orsolya, additional, Fehér, Orsolya, additional, Malik, Péter, additional, Ursu, Krisztina, additional, Kertész, Péter, additional, Kepner, Anett, additional, Martina, Máté, additional, Süli, Tamás, additional, Lanszki, Zsófia, additional, Tóth, Gábor Endre, additional, Kuczmog, Anett, additional, Somogyi, Balázs, additional, Jakab, Ferenc, additional, and Kemenesi, Gábor, additional

Published
2020
Full Text
View/download PDF

48. Magyarországra behurcolt trópusi arbovírusfertőzések 2016 és 2020 között.

Author

Nagy, Orsolya, Nagy, Anna, Tóth, Szilvia, Koroknai, Anita, and Takács, Mária

Abstract

Copyright of Hungarian Medical Journal / Orvosi Hetilap is the property of Akademiai Kiado and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results